Literature DB >> 11045573

Expression of transforming growth factor-beta and tumor necrosis factor-alpha in the plasma and tissues of mice with lupus nephritis.

K Yamamoto1, D J Loskutoff.   

Abstract

Although elevated levels of transforming growth factor-beta (TGF-beta) and tumor necrosis factor-alpha (TNF-alpha) have been implicated in renal disease, the tissue distribution and cellular localization of the induced cytokines is not well established. In this study, we investigated the expression of these cytokines during the progression of lupus nephritis in MRL lpr/lpr mice. The concentration of both cytokines increased in the plasma of these animals in an age-dependent manner, and there was an age-dependent induction of TGF-beta and TNF-alpha mRNAs in their kidneys. Although the increase in TGF-beta mRNA was specific for the kidney, the increase in TNF-alpha mRNA was widespread and also could be demonstrated in the liver, lung, and heart. In situ hybridization analysis of renal tissues from the lupus-prone mice localized TGF-beta mRNA to the glomerulus, and more specifically, to resident glomerular cells and inflammatory cells infiltrating periglomerular spaces in the nephritic lesions. The signals for TNF-alpha mRNA were detected only in inflammatory cells and were distributed throughout the nephritic kidney. Plasminogen activator inhibitor-1 (PAI-1) is known to be elevated in the glomeruli of MRL lpr/lpr mice, and intraperitoneal administration of either TGF-beta or TNF-alpha into normal mice markedly induced the expression of this potent inhibitor of fibrinolysis in renal glomerular or tubular cells in vivo. These results suggest that the increased renal expression of both cytokines may contribute to the development of lupus nephritis in this model and raise the possibility that PAI-1 may be involved. The fact that TGF-beta is specifically induced in the kidney whereas TNF-alpha increases in a variety of tissues, supports the hypothesis that the renal specificity of this disorder reflects the abnormal expression of TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11045573     DOI: 10.1038/labinvest.3780166

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

Review 1.  Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review.

Authors:  Susan Yung; Tak Mao Chan
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

2.  The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis.

Authors:  Kristin Moreth; Rebekka Brodbeck; Andrea Babelova; Norbert Gretz; Tilmann Spieker; Jinyang Zeng-Brouwers; Josef Pfeilschifter; Marian F Young; Roland M Schaefer; Liliana Schaefer
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

3.  Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody.

Authors:  Y Takeda; M Takeno; M Iwasaki; H Kobayashi; Y Kirino; A Ueda; K Nagahama; I Aoki; Y Ishigatsubo
Journal:  Clin Exp Immunol       Date:  2004-11       Impact factor: 4.330

4.  Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis.

Authors:  Chenzhu Zhang; Tsz Wai Tam; Mel Km Chau; Cristina Alexandra García Córdoba; Susan Yung; Tak Mao Chan
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

5.  T cells, adhesion molecules and modulation of apoptosis in visceral leishmaniasis glomerulonephritis.

Authors:  Francisco A L Costa; Maria G Prianti; Teresa C Silva; Silvana M M S Silva; José L Guerra; Hiro Goto
Journal:  BMC Infect Dis       Date:  2010-05-11       Impact factor: 3.090

6.  Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.

Authors:  Kyosuke Takeshita; Mutsuharu Hayashi; Shigeo Iino; Takahisa Kondo; Yasuya Inden; Mitsunori Iwase; Tetsuhito Kojima; Makoto Hirai; Masafumi Ito; David J Loskutoff; Hidehiko Saito; Toyoaki Murohara; Koji Yamamoto
Journal:  Am J Pathol       Date:  2004-02       Impact factor: 4.307

7.  Lupus nephritis: an overview of recent findings.

Authors:  Alberto de Zubiria Salgado; Catalina Herrera-Diaz
Journal:  Autoimmune Dis       Date:  2012-03-22

8.  Tacrolimus Protects Podocytes from Injury in Lupus Nephritis Partly by Stabilizing the Cytoskeleton and Inhibiting Podocyte Apoptosis.

Authors:  Ruyi Liao; Qinghua Liu; Zhihua Zheng; Jinjin Fan; Wenxing Peng; Qingyu Kong; Huijuan He; Shicong Yang; Wenfang Chen; Xueqing Tang; Xueqing Yu
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

9.  Urinary Neutrophil Gelatinase-Associated Lipocalin to Monitor Lupus Nephritis Disease Activity.

Authors:  Hani Susianti; Jullyanny W Wijaya; Ati Rastini; Kusworini Handono; Atma Gunawan; Handono Kalim
Journal:  Biomark Insights       Date:  2015-09-06

10.  Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.

Authors:  Samir V Parikh; Ana Malvar; Huijuan Song; Valeria Alberton; Bruno Lococo; Jay Vance; Jianying Zhang; Lianbo Yu; Brad H Rovin
Journal:  Lupus Sci Med       Date:  2015-11-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.